- Home
- PNW vs JAZZ Comparison
PNW vs JAZZ Comparison
Compare PNW & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PNW | JAZZ |
|---|---|---|
| Founded | 1985 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1B | 10.4B |
| IPO Year | 1994 | 2007 |
Fundamental Metrics
Financial Performance| Metric | PNW | JAZZ |
|---|---|---|
| Price | $103.13 | $203.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 13 |
| Target Price | $98.77 | ★ $216.92 |
| AVG Volume (30 Days) | ★ 917.2K | 843.7K |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.50% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 5.05 | N/A |
| Revenue | ★ $5,339,939,000.00 | $1,618,693,000.00 |
| Revenue This Year | $5.43 | $6.13 |
| Revenue Next Year | $6.82 | $7.75 |
| P/E Ratio | $20.60 | ★ N/A |
| Revenue Growth | ★ 4.20 | N/A |
| 52 Week Low | $85.32 | $101.22 |
| 52 Week High | $104.92 | $204.13 |
Technical Indicators
Market Signals| Indicator | PNW | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 56.43 | 67.30 |
| Support Level | $86.28 | $159.78 |
| Resistance Level | $104.03 | N/A |
| Average True Range (ATR) | 1.63 | 4.91 |
| MACD | 0.04 | 0.90 |
| Stochastic Oscillator | 68.23 | 81.07 |
Price Performance
Historical ComparisonAbout PNW Pinnacle West Capital Corporation
Pinnacle West is a holding company whose principal subsidiary is Arizona Public Service, a vertically integrated electric utility serving approximately 1.4 million customers across a 35,000-square-mile territory in central Arizona, including the Phoenix area. APS owns or leases 6.5 gigawatts of power generation capacity, including a 29% ownership stake in one of the largest nuclear plants in the US, Palo Verde. Half of the electricity that APS supplies to customers comes from clean energy sources, including nuclear.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.